AbCellera Biologics Inc. ABCL Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s additional paid-in capital?
- AbCellera Biologics Inc. (ABCL) reported additional paid-in capital of $196.62M in Q1 2026.
- How has AbCellera Biologics Inc.'s additional paid-in capital changed year-over-year?
- AbCellera Biologics Inc.'s additional paid-in capital increased by 16.6% year-over-year, from $168.6M to $196.62M.
- What is the long-term trend for AbCellera Biologics Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s additional paid-in capital has grown at a 101.8% compound annual growth rate (CAGR), from $5.92M to $198.28M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.